WT161 (WT-161)

Background Information:

WT161 is a potent,selective,and bioavailable HDAC6 inhibitor. It was
created to study the mechanism of action of HDAC6 inhibition in MM
(Multiple Myeloma) alone and in combination with Bortezomib (BTZ). WT161
in combination with BTZ triggers significant accumulation of
polyubiquitinated proteins and cell stress, followed by caspase
activation and apoptosis. More importantly, this combination treatment
was effective in BTZ-resistant cells and in the presence of bone marrow
stromal cells, which have been shown to mediate MM cell drug resistance.
The activity of WT161 was confirmed in our human MM cell xenograft
mouse model and established the framework for clinical trials of the
combination treatment to improve patient outcomes in MM. (Ref.1)

Reference:

1. Teru Hideshima, et al, Discovery of selective small-molecule HDAC6
inhibitor for overcoming proteasome inhibitor resistance in multiple
myeloma, PNAS, 2016, vol. 113, no. 46, p13162–13167.

APIM050346: WT161 (WT-161)

CAS No.: 1206731-57-8.
Molecular Formula: C27H30N4O3.
Molecular Weight: 458.6 (or refer to Certificate of Analysis, batch-specific).
Purity: >98% by HPLC at 254nm.
QC: HPLC-MS, NMR, and quantitative elemental analysis report.
Solubility: Refer to Certificate.
Storage: Refer to Certificate.